Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan

International Journal of Risk and Safety in Medicine

Volumn 21, Issue 3, 2009, Pages 161-167

  Nishimura, Tsutomu ^a   Tada, Harue ^a   Fukushima, Masanori ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b Translational Research Informatics Center   (Japan)

Author keywords

Adverse drug reaction; Erlotinib; Gefitinib; Interstitial lung disease; Pharmacovigilance; Post marketing surveillance

Indexed keywords

ERLOTINIB; GEFITINIB;

ADVANCED CANCER; ANOREXIA; ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; LIVER DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; NONHUMAN; RASH; RECURRENT CANCER; STOMATITIS; VOMITING;

EID: 70349102039     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: 10.3233/JRS-2009-0475     Document Type: Article

References (16)

1. AstraZeneca K.K., Information about Iressa tablets 250 (in Japanese), available at: http://www.info.pmda.go.jp/shinyaku/g020706/index.html? (accessed January 6, 2009).
2. AstraZeneca K.K., The list of adverse drug reaction about Iressa tablets 250, November 2007 (in Japanese).
3. AstraZeneca K.K., The trend in the incidence of interstitial lung diseases and interstitial pneumonia (in Japanese), available at: http://www.astrazeneca.co.jp/activity/other/detail/03-02-10b.html (accessed June 1, 2009).
4. P. Camus, S. Kudoh and M. Ebina, Interstitial lung disease associated with drug therapy, Br. J. Cancer 91 (2004), S18-S23. (Pubitemid 39331428)
5. Chugai Pharmaceutical Co., Ltd., Information for Erlotinib® tablet, 1st edn, July 2002 (in Japanese).
6. Chugai Pharmaceutical Co., Ltd., List of adverse drug reactions among users of the Tarceva tablet (in Japanese), available at: http://www.chugai- pharm.co.jp/hc/di/scholar/item/drug-data/tar/se/diag/20090528/tar-diag.pdf (accessed June 1, 2009).
7. Chugai Pharmaceutical Co., Ltd., List of deaths among users of the Tarceva tablet (in Japanese), available at: http://www.chugai-pharm.co.jp/hc/di/ scholar/item/drug-data/tar/se/sibo/20090528/tar-mortality.pdf (accessed June 1, 2009).
8. Chugai Pharmaceutical Co., Ltd., The result of interim analysis of mandatory total surveillance, available at: http://www.chugai-pharm.co.jp/hc/di/ scholar/item/drug-data/tar/report/pms/tar-tokuteiResult-2nd.pdf (accessed June 1, 2009).
9. S. Kudoh and A. Yoshimura, Current status and problems of anticancer drug-induced lung injuries, Jpn. J. Cancer Chemother. 33 (2006), 881-886 (in Japanese).
10. Ministry of Health, Labor and Welfare, Minutes of the fourth official meeting to discuss the gefitinib problem, March 24, 2005 (in Japanese).
11. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, H.J. Au, P. Murawa, D. Walde, R.A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski and W. Parulekar; National Cancer Institute of Canada Clinical Trials Group, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol. 25 (2007), 1960-1966. (Pubitemid 46972777)
12. T. Nishimura, H. Tada, M. Nakagawa, S. Teramukai, S. Matsui and M. Fukushima, Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures, Pharm. Pract. 4 (2006), 168-178.
13. Pharmaceuticals and Medical Devices Agency, The report of new drug application review for Erlotinib, August 15, 2007 (in Japanese), available at: http://www.info.pmda.go.jp/shinyaku/g071008/45004500-21900AMX01758-A100-1.pdf (accessed January 6, 2009).
14. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabárbara and L. Seymour; National Cancer Institute of Canada Clinical Trials Group, Erlotinib in previously treated non-small-cell lung cancer, N. Engl. J. Med. 353 (2005), 123-132.
15. K. Yamamoto, S. Matsumoto, H. Tada, K. Yanagihara, S. Teramukai, T. Takemura and M. Fukushima, A data capture system for outcomes studies that integrates with electronic health records: development and potential uses, J. Med. Syst. 32 (2008), 423-427.
16. S. Yoshida, The results of gefitinib prospective investigation, Med. Drug J. 41 (2005), 772-789.